Polish Journal of Public Health

Review Article, Pol J Public Health 2020;130: 61-64

Katarzyna Walczak, Anna Makuch-Kocka, Justyna Ziemińska

Department of Pharmacology, Medical University of Lublin, Poland

10.2478/pjph-2020-0014

© 2020 Medical University of Lublin. This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)

Abstract

The development of an effective treatment for COVID-19 is now one of the main tasks of scientists and doctors from all over the world. The rapidly spreading SARS-CoV2 virus infection is a serious health problem among the public. Similarity of SARSCoV2 to MERS-CoV and SARS-CoV may suggest the effectiveness of COVID-19 treatment with drugs used to fight infections of previously identified Coronaviridae viruses. On the basis of gained experience and new clinical trials, the Polish Society of Epidemiologists and Infectious Diseases Physicians has created guidelines for the treatment of COVID-19. The recommendations concern primary and supportive treatment at different stages of the disease. This article provides a brief review of the molecular mechanisms of drugs currently used in Poland for the treatment of COVID-19.

Keywords: COVID-19, SARS-CoV-2 virus, remdesivir, tocilizumab, convalescent plasma, corticosteroids, anticoagulants.